RO.SW
Roche Holding AG [RO.SW] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
RO.SW Stock Summary
Top 10 Correlated ETFs
RO.SW
Top 10 Correlated Stocks
RO.SW
In the News
RO.SW Financial details
Company Rating
Strong Buy
Market Cap
182.34B
Income
23.92B
Revenue
122B
Book val./share
36.77
Cash/share
13.18
Dividend
9.5
Dividend %
3.51%
Employees
103.61K
Optionable
No
Shortable
Yes
Earnings
25 Jul 2024
P/E
19.74
Forward P/E
-
PEG
2.15
P/S
3.21
P/B
8.21
P/C
17.94
P/FCF
15.17
Quick Ratio
0.71
Current Ratio
1.18
Debt / Equity
1.01
LT Debt / Equity
0.75
-
-
EPS (TTM)
29.81
EPS next Y
-
EPS next Q
-
EPS this Y
-7.34%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-1.81%
Revenue last 5Y
-1.63%
Revenue Q/Q
-2.83%
EPS Q/Q
-38.75%
-
-
-
-
SMA20
-3.86%
SMA50
-5.45%
SMA100
-5.29%
Inst Own
0%
Inst Trans
0%
ROA
13%
ROE
40%
ROC
0.34%
Gross Margin
73%
Oper. Margin
31%
Profit Margin
18%
Payout
69%
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
229.4-318.0
52W High
-25.66%
52W Low
+3.23%
RSI
42.15
Rel Volume
0.02
Avg Volume
33.58K
Volume
829
Perf Week
-0.51%
Perf Month
-5.44%
Perf Quarter
-6.71%
Perf Half Y
-11.53%
-
-
-
-
Beta
0.148
-
-
Volatility
2.53%, 6.65%
Prev Close
-0.42%
Price
236.4
Change
-1.34%
RO.SW Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 74.48 | 68.21 | 73.88 | 79.1 | 73.49 | |
| Net income per share | 15.77 | 16.72 | 16.39 | 15.53 | 14.39 | |
| Operating cash flow per share | 26.15 | 21.24 | 24.2 | 22.36 | 19.39 | |
| Free cash flow per share | 22.06 | 13.42 | 18.85 | 16.67 | 13.57 | |
| Cash per share | 13.84 | 14.43 | 15.33 | 12.21 | 13.15 | |
| Book value per share | 38.26 | 42.5 | 28.81 | 34.99 | 36.69 | |
| Tangible book value per share | 17.31 | 10.83 | -6.34 | 0.86 | -0.43 | |
| Share holders equity per share | 38.26 | 42.5 | 28.81 | 34.99 | 36.69 | |
| Interest debt per share | 17.9 | 17.51 | 37.49 | 32.83 | 37.96 | |
| Market cap | 263.31B | 265.05B | 347.48B | 286.72B | 208.86B | |
| Enterprise value | 272.81B | 274.73B | 373.18B | 308.27B | 234.26B | |
| P/E ratio | 19.51 | 18.54 | 24.94 | 23.08 | 18.16 | |
| Price to sales ratio | 4.13 | 4.54 | 5.53 | 4.53 | 3.56 | |
| POCF ratio | 11.76 | 14.6 | 16.89 | 16.03 | 13.48 | |
| PFCF ratio | 13.94 | 23.11 | 21.69 | 21.5 | 19.26 | |
| P/B Ratio | 8.04 | 7.29 | 14.19 | 10.24 | 7.12 | |
| PTB ratio | 8.04 | 7.29 | 14.19 | 10.24 | 7.12 | |
| EV to sales | 4.28 | 4.71 | 5.94 | 4.87 | 3.99 | |
| Enterprise value over EBITDA | 10.92 | 12.32 | 17.17 | 14.01 | 11.82 | |
| EV to operating cash flow | 12.19 | 15.13 | 18.14 | 17.23 | 15.12 | |
| EV to free cash flow | 14.45 | 23.95 | 23.29 | 23.11 | 21.6 | |
| Earnings yield | 0.05 | 0.05 | 0.04 | 0.04 | 0.06 | |
| Free cash flow yield | 0.07 | 0.04 | 0.05 | 0.05 | 0.05 | |
| Debt to equity | 0.45 | 0.4 | 1.29 | 0.92 | 1.01 | |
| Debt to assets | 0.18 | 0.17 | 0.34 | 0.29 | 0.33 | |
| Net debt to EBITDA | 0.38 | 0.43 | 1.18 | 0.98 | 1.28 | |
| Current ratio | 1.3 | 1.3 | 0.93 | 1.24 | 1.35 | |
| Interest coverage | 33.92 | 40.48 | 50.68 | 29.89 | 19.75 | |
| Income quality | 1.66 | 1.27 | 1.48 | 1.44 | 1.35 | |
| Dividend Yield | 0.03 | 0.03 | 0.02 | 0.03 | 0.04 | |
| Payout ratio | 0.55 | 0.54 | 0.56 | 0.6 | 0.66 | |
| Sales general and administrative to revenue | 0.04 | 0.04 | 0.04 | 0.22 | 0.25 | |
| Research and developement to revenue | 0.2 | 0.21 | 0.22 | 0.22 | 0.23 | |
| Intangibles to total assets | 0.25 | 0.35 | 0.37 | 0.36 | 0.37 | |
| Capex to operating cash flow | -0.16 | -0.37 | -0.22 | -0.25 | -0.3 | |
| Capex to revenue | -0.05 | -0.11 | -0.07 | -0.07 | -0.08 | |
| Capex to depreciation | -0.82 | -1.47 | -1.02 | -1.19 | -1.34 | |
| Stock based compensation to revenue | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Graham number | 116.5 | 126.45 | 103.07 | 110.56 | 108.99 | |
| ROIC | 0.37 | 0.29 | 0.26 | 0.28 | 0.24 | |
| Return on tangible assets | 0.22 | 0.26 | 0.24 | 0.22 | 0.2 | |
| Graham Net | -28.27 | -25.3 | -44.23 | -39.58 | -41.41 | |
| Working capital | 7.14B | 7.54B | -2.79B | 6.58B | 8.62B | |
| Tangible asset value | 14.82B | 9.26B | -5.39B | 690M | -345M | |
| Net current asset value | -15.97B | -13.42B | -28.35B | -22.32B | -23.76B | |
| Invested capital | 0.45 | 0.4 | 1.29 | 0.92 | 1.01 | |
| Average receivables | 10.56B | 11.3B | 12.2B | 13.26B | 13.42B | |
| Average payables | 3.13B | 3.25B | 3.58B | 3.85B | 3.69B | |
| Average inventory | 6.34B | 6.62B | 7.45B | 8.16B | 8.18B | |
| Days sales outstanding | 62.21 | 73.47 | 73.53 | 79.98 | 80.69 | |
| Days payables outstanding | 66.68 | 74.03 | 71.21 | 74.81 | 81.32 | |
| Days of inventory on hand | 127.13 | 160.56 | 142.92 | 166.74 | 178.81 | |
| Receivables turnover | 5.87 | 4.97 | 4.96 | 4.56 | 4.52 | |
| Payables turnover | 5.47 | 4.93 | 5.13 | 4.88 | 4.49 | |
| Inventory turnover | 2.87 | 2.27 | 2.55 | 2.19 | 2.04 | |
| ROE | 0.41 | 0.39 | 0.57 | 0.44 | 0.39 | |
| Capex per share | -4.09 | -7.82 | -5.35 | -5.69 | -5.82 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2021-12-31 | 2022-06-30 | 2022-12-31 | 2023-06-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 37.98 | 39.9 | 38.77 | 37.27 | 36.3 | |
| Net income per share | 7.25 | 10.54 | 4.87 | 8.93 | 5.47 | |
| Operating cash flow per share | 14.91 | 11.47 | 10.77 | 9.5 | 9.92 | |
| Free cash flow per share | 12.01 | 8.97 | 7.61 | 7.03 | 6.56 | |
| Cash per share | 15.42 | 8.41 | 12.22 | 9.4 | 13.18 | |
| Book value per share | 28.98 | 31.12 | 35.03 | 33.19 | 36.77 | |
| Tangible book value per share | -6.38 | -6.31 | 0.86 | 0.11 | -0.43 | |
| Share holders equity per share | 28.98 | 31.12 | 35.03 | 33.19 | 36.77 | |
| Interest debt per share | 37.51 | 34.61 | 32.54 | 32.28 | 37.53 | |
| Market cap | 345.42B | 298.15B | 286.43B | 234.59B | 208.4B | |
| Enterprise value | 371.12B | 321.58B | 307.98B | 256.25B | 233.81B | |
| P/E ratio | 14.09 | 8.74 | 18.4 | 8.22 | 11.95 | |
| Price to sales ratio | 10.76 | 9.23 | 9.24 | 7.88 | 7.2 | |
| POCF ratio | 27.42 | 32.12 | 33.28 | 30.92 | 26.36 | |
| PFCF ratio | 34.05 | 41.08 | 47.1 | 41.79 | 39.84 | |
| P/B Ratio | 14.11 | 11.84 | 10.23 | 8.85 | 7.11 | |
| PTB ratio | 14.11 | 11.84 | 10.23 | 8.85 | 7.11 | |
| EV to sales | 11.57 | 9.96 | 9.94 | 8.61 | 8.08 | |
| Enterprise value over EBITDA | 36.28 | 26.41 | 31.35 | 22.87 | 27.14 | |
| EV to operating cash flow | 29.46 | 34.64 | 35.78 | 33.78 | 29.57 | |
| EV to free cash flow | 36.59 | 44.31 | 50.65 | 45.65 | 44.7 | |
| Earnings yield | 0.02 | 0.03 | 0.01 | 0.03 | 0.02 | |
| Free cash flow yield | 0.03 | 0.02 | 0.02 | 0.02 | 0.03 | |
| Debt to equity | 1.29 | 1.1 | 0.92 | 0.96 | 1.01 | |
| Debt to assets | 0.34 | 0.32 | 0.29 | 0.3 | 0.33 | |
| Net debt to EBITDA | 2.51 | 1.92 | 2.19 | 1.93 | 2.95 | |
| Current ratio | 0.93 | 1.11 | 1.24 | 1.18 | 1.35 | |
| Interest coverage | 47.38 | 39.81 | 22.58 | 23.35 | 16.29 | |
| Income quality | 2.06 | 1.09 | 2.21 | 1.06 | 1.81 | |
| Dividend Yield | 0 | 0.02 | 0 | 0.03 | 0 | |
| Payout ratio | 0 | 0.87 | 0 | 1.07 | 0.01 | |
| Sales general and administrative to revenue | 0.04 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0.22 | 0.21 | 0.24 | 0.21 | 0.24 | |
| Intangibles to total assets | 0.37 | 0.39 | 0.36 | 0.36 | 0.37 | |
| Capex to operating cash flow | -0.19 | -0.22 | -0.29 | -0.26 | -0.34 | |
| Capex to revenue | -0.08 | -0.06 | -0.08 | -0.07 | -0.09 | |
| Capex to depreciation | -1.13 | -1.06 | -1.32 | -1.13 | -1.55 | |
| Stock based compensation to revenue | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 | |
| Graham number | 68.76 | 85.91 | 61.94 | 81.67 | 67.27 | |
| ROIC | 0.13 | 0.16 | 0.12 | 0.15 | 0.11 | |
| Return on tangible assets | 0.1 | 0.16 | 0.07 | 0.13 | 0.08 | |
| Graham Net | -44.49 | -47.61 | -39.62 | -42.24 | -41.5 | |
| Working capital | -2.79B | 2.91B | 6.58B | 4.77B | 8.62B | |
| Tangible asset value | -5.39B | -5.11B | 690M | 87M | -345M | |
| Net current asset value | -28.35B | -27.47B | -22.32B | -23.05B | -23.76B | |
| Invested capital | 1.29 | 1.1 | 0.92 | 0.96 | 1.01 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 0 | 0 | 0 | 0 | 0 | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 35.48 | 30.87 | 40.27 | 34.33 | 40.37 | |
| Days payables outstanding | 39.87 | 35.96 | 38.24 | 48.41 | 47.01 | |
| Days of inventory on hand | 66.34 | 76.54 | 85.23 | 101.44 | 84.23 | |
| Receivables turnover | 2.54 | 2.92 | 2.23 | 2.62 | 2.23 | |
| Payables turnover | 2.26 | 2.5 | 2.35 | 1.86 | 1.91 | |
| Inventory turnover | 1.36 | 1.18 | 1.06 | 0.89 | 1.07 | |
| ROE | 0.25 | 0.34 | 0.14 | 0.27 | 0.15 | |
| Capex per share | -2.91 | -2.5 | -3.16 | -2.47 | -3.36 |
RO.SW Frequently Asked Questions
What is Roche Holding AG stock symbol ?
Roche Holding AG is a CH stock and trading under the symbol RO.SW
What is Roche Holding AG stock quote today ?
Roche Holding AG stock price is $236.4 today.
Is Roche Holding AG stock public?
Yes, Roche Holding AG is a publicly traded company.
Company Profile
- Volume Average 33.58K
- Market Capitalization 182.34B
- Employee 103.61K
- CEO Dr. Thomas Schinecker
- Headquarters Basel,CH
- IPO Date 1995-08-03
-
Website
https://www.roche.com 
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, Austria, Netherlands, the United Kingdom, France, Belgium, and internationally. The company offers pharmaceutical products for treating oncology, neuroscience, infectious, immunology, cardiovascular and metabolism, ophthalmology, and respiratory, as well as anemia, cancer, dermatology, hemophilia, inflammatory and autoimmune, neurological, and transplantation. It also offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases. In addition, the company supplies diagnostic instruments and reagents. The company was founded in 1896 and is headquartered in Basel, Switzerland.
